AlarconJane Knight Lowe
    Emeritus Professor of Medicine



    Faculty Office Towers, room 830
    510 20th Street South
    Birmingham, Alabama 35294-3408

    Telephone:(205) 422-0983



    BS,Facultad de Ciencias, Universidad Nacional Mayor de San Marcos. Lima, Perú, 1961
    MD,Facultad de Medicina, Universidad Peruana Cayetano Heredia. Lima, Perú, 1967
    Fellowship (Clinical), Department of Medicine, Johns Hopkins University, School of Medicine. Baltimore City Hospitals, Baltimore, MD, 1969
    Master in Public Health (M.P.H.), Johns Hopkins University, School of Hygiene and Public Health, Baltimore, MD, 1972
    Doctor in Medicine, Universidad Peruana Cayetano Heredia. Lima, Perú, 1972
    Fellowship (Research), Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, 1981


    Selected Honors and Awards

    1964, Diploma presented by the Peruvian Government recognizing voluntary work at the Sierra Indian Communities of Cuzco, Perú

    1971-1972, Recipient of Merck, Sharp & Dohme Scholarship, Master of Public Health, Johns Hopkins University. Baltimore, MD

    1980, American Rheumatism Association Senior Rheumatology Scholar Award

    1988, Mexican Society of Rheumatology, Professor of the Year

    1997, Virginia Engalichteff Award for Impact on Quality of Life, Arthritis Foundation. Denver, CO

    2003, Outstanding Faculty-The University of Alabama at Birmingham Women's Center

    2004, Pfizer Visiting Professor - Vanderbilt University- Nashville, TN

    2006, Keynote Speaker,  Pan American League of Associations of Rheumatologists. Lima, Perú

    2008, ACR Master, ACR Annual Scientifie Meeting, San Francisco, CA

    2008, PANLAR Master, PANLAR Scientific Meeting, Guatemala City, Guatemala

    2009, Dean's Award for Academic Execellence. The University of Alabama at Birmingham, Birmingham, Alabama

    2000-2010, Visiting Professor, Argentinean Society of Rheumatology

    2011, Mexican Society of Rheumatology: Honoring Latin American Masters of the American College of Rheumatology; Cancún, Mexico
             Speaker, Universidad Peruana Cayetano Heredia, 50th year Anniversary. Lima, Perú
             Evelyn Hess Award for Excellence in Lupus Research. Lupus Foundation of America. Chicago, IL

    2012, Leader of Peruvian Rheumatology. Sociedad Peruana de Reumatología; Lima, Perú

    2013, Visiting Professor. University of Washington; Seattle, WA.
              Dr. Honoris Causa. Universidad Nacional de Asunción; Asunción, Paraguay.
              Associate member, Peruvian Academy of Medicine

    2014, Visiting Professor (38th Annual Michael Einbender Distinguished Lectureship. University Missouri; Columbus, MO
              American College of Rheumatology Distinguished Rheumatology Investigator Award, Boston, MA

    2015, Peruvian College of Physicians: Recognition as Leader of Peruvian Rheumatology
             The Servicio de Inmuno-Reumatología, at Hospital Nacional Cayetano Heredia from Universidad Peruana Cayetano Heredia is named: Graciela S. Alarcón

    2016, The University of Alabama at Birmingham establishes the Graciela S. Alarcón, MD, MPH Lupus Research Fund
              The Halsted R. Holman Award for Excellence on Clinical Research in Lupus. LUPUS 2016, Armonk, NY.
              Distinguished Service Award for promoting the goals of the Global Alliance for Musculoskeletal Health.


    Clinical, Research and Education Interests

    I joined the Faculty at UAB in 1981 after being a Research Fellow for about 18 months. I am currently Emeritus Professor and although not in Birmingham, I am still involved in mentoring fellows and collaborating with the LFA, LCTC, GLADEL as the need arises. During my stay at UAB and prior to that at my alma mater (Universidad Peruana Cayetano Heredia in Lima, Perú), I have been involved in the training of clinical and research fellows. In fact, after my US training (1968-1972), I started the first training program in Rheumatology and the first Rheumatology Unit in Perú. Whether in Perú or in the US, I have attended their clinics, have rounded with them, and foremost I have been stimulating them to always keep an open and inquisitive mind in dealing with their day-to-day activities being those in the clinic or in the research setting. I can say that over 60% of the fellows graduating from UAB between 1981 and the early 2000's, when I became more involved in the training of clinical research fellows (vide infra), have had the opportunity to publish their clinical experience under my mentorship and with my unconditional support. Of course, not all of them have become academicians or researchers in their own right, but I have been quick to point out to all of them that the proper appreciation of what research entails or the amount of work that goes into a published paper, can only come from personally going through the same experience.

    Although I have been involved in mentoring Junior Faculty and clinical research fellows in the past, it has been only since 2002 that I have had the opportunity to LUMINAcollaboratorshave the funding to support them for the conduct of research in lupus. These fellows have used the very rich database from LUMINA, a multi-ethnic cohort of lupus patients established in collaboration with Drs. John Reveille (UT-Houston, TX) and Luis Vilá (U- Puerto Rico, San Juan, PR) in the early 1990's. Participating in the training of these young physicians while continuing to mentor Junior Faculty and clinical fellows, as time permits, has been, and continues to be, one of the most rewording but also challenging experiences of my academic life as a rheumatologist. For the most part, these trainees have come with limited research experience; despite that, they have performed spectacularly well. In addition to participating in data collection on patients from the cohort, they have generated their own sub-projects and taken them to completion including the Gladel 2publication of their findings in prestigious rheumatology journals. The fruits of LUMINA have been summarized in a special article published in the Journal Lupus in 2008. Moreover, the salient finding from the LUMINA study were highlighted in an article published in The Rheumatologist in the Spring of 2011. At the present time, I continue to be involved in the work of the fellows that trained with me over the last few years (Drs. Durán-Barragán, González, Pons-Estel and Burgos) who are conducting research in lupus in their country of origin. In parallel I am assisting the LCTC in the establishment of a national registry of lupus patients (US and Canada). Finally, over the last few years I have developed a very close relationship with GLADEL (for Grupo Latinoamericano de Estudio de Lupus or Latin American Group for the Study of Lupus), assisting them in the utilization of their rich database. This group with the support of PANLAR is now developing the Latin American treatment guidelines for lupus, effort in which I am quite involved.



    Click here for a more complete list of publications. Below are selected papers

    Ugarte-Gil MF, Pons-Estel GJ, Molineros J, Wojdyla D, McGwin G Jr, Nath SK, Pons-Estel BA, Alarcón-Riquelme M, Alarcón GS. 2016. Disease features and outcomes in United States lupus patients of Hispanic origin and their Mestizo counterparts in Latin America: A commentary. Rheumatology (Oxford). 55: 436-40. PMID: 26412809; PMC5009444

    Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sánchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin G Jr, Magder LS. 2012. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64: 2677-86. PMID: 22553077; PMC3409311

    Shinjo SK, Bonfá E, Wojdyla D, Borba EF, Ramirez LA, Scherbarth HR, Brenol JC, Chacón-Diaz R, Neira OJ, Berbotto GA, De La Torre IG, Acevedo-Vázquez EM, Massardo L, Barile-Fabris LA, Caeiro F, Silveira LH, Sato EI, Buliubasich S, Alarcón GS, Pons-Estel BA; Grupo Latino Americano de Estudio del Lupus Eritematoso (Gladel). 2010. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum. 62(3):855-62. PMID: 20131238

    Burgos PI, Perkins EL, Pons-Estel GJ, Kendrick SA, Liu JM, Kendrick WT, Cook WJ, Julian BA, Alarcón GS, Kew II CE. 2009. Risk Factors and Impact of Recurrent Lupus Nephritis in Transplanted Patients with Systemic Lupus Erythematosus: Data from a Single US Institution. Arthritis Rheum 60:2757-66. PMID: 19714623; PMC2771574

    Alarcón GS, McGwin G, Jr., Bertoli AM, Fessler BJ, Calvo-Alén J, Bastian HM, Vilá LM, Reveille JD, for the LUMINA Study Group. 2007. Effect of hydroxychloroquine in the survival of patients with systemic lupus erythematosus. Data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 66:1168-72. PMID: 17389655; PMC1955128


  • Ball-2011Professor Emeritus of Medicine


    Faculty Office Tower, room 827

    Telephone: (205) 934-4703




    Dr. Ball joined the UAB faculty in 1965 and was named the Jane Knight Lowe Professor in Medicine in Rheumatology in 1986. UAB recognized and honored his contributions to academic excellence by naming him professor emeritus in 1997.

    In addition to faithfully serving UAB, Dr. Ball has admirably served in leadership roles in numerous professional organizations, committees, and boards. Dr. Ball was the interim director of the division for 18 months in 1995-96. Highly respected by his colleagues as well as his patients, Dr. Ball has cultivated continuing program growth and excellence with a commitment to quality patient care as well as research and education.







  • Ballesteros_Tato_1Assistant Professor of Medicine

    Division of Clinical Immunology and Rheumatology


    Shelby Building, Room 413
    1825 University Boulevard

    Telephone: (205) 975-4643

    Fax: (205) 975-3322

    Email: aballest@uab.edu



    B.S. (Biology): Vigo University, Spain, 2001
    Ph.D. (Microbiology & Immunology): Universidad Autonoma de Madrid, Spain, 2007
    Postdoctoral Fellow:Trudeau Institute, Saranac Lake, NY, 2008
    Postdoctoral Fellow:University of Rochester, NY, 2008-2012.


    Research Interests

    The generation of long-lived, high affinity antibodies is required for protective immunity to most viruses and for protection after vaccination. Thus, it is essential to understand the mechanisms that control the generation of long-lasting protective antibody (Ab) responses. T follicular helper (Tfh) cells, a distinct CD4+ T cell subset that expresses high levels of CXCR5 and localizes in the B cell follicles, play an essential role on promoting long-lived Ab responses. In fact, in the absence of Tfh cells, long-term Ab responses are impaired and protection to pathogens compromised. Therefore, it is essential that we understand how to manipulate Tfh responses in order to improve the efficacy of vaccines. However, despite significant advances in the field, our understanding of how Tfh cells responses are initiated is very limited.

    Recent studies suggest that Tfh cells are initially primed by dendritic cells (DCs), suggesting that we may be able to develop adjuvants that preferentially activate DCs to promote Tfh cell priming or target vaccine antigens to those DCs that preferentially induce Tfh cells. Unfortunately, we do not know what signals direct the DCs to promote Tfh cell differentiation or which specific subsets of DCs prime Tfh cell responses. Thus, one of the goals of my lab is to determine the cellular interactions, the environmental cues and the molecular mechanisms that control the differential capacity of distinct populations of DCs to regulate Tfh cell responses in different models of infection and autoimmune disease. This knowledge will help us to determine the nature of adjuvants that can be used to boost Tfh cell responses to tumors, pathogens and vaccines.

    A second project in my lab focuses on the potential clinical benefits of low-dose IL-2 administration to treat autoimmune disease and the mechanisms underlying these effects. Recent studies indicate that low-dose IL-2 treatment suppresses unwanted immune responses in mice and humans, thus evidencing the potential of IL-2 to treat autoimmune disorders (reviewed by us in Immunotherapy. 2014). Increased regulatory T cell activity is one of the potential mechanisms by which low-dose IL-2 immunotherapy induces immunosuppression. However data obtained in my lab indicate that exogenous IL-2 administration prevents aberrant accumulation of Tfh and GC B cell in lupus-prone mice. Our results demonstrate an unexpected immunosuppressive function of IL- 2 that is independent on its role on Treg homeostasis, and provide an alternative mechanism to explain the clinical benefits of IL-2 immunotherapies to treat antibody-mediated autoimmune disorders. These data offer new insights into how polymorphisms in the IL-2 and IL-2R genes can affect self-reactive Tfh and B cell responses and influence the development of autoimmune disease manifestations. We are now exploring the potential therapeutic use of low doses of IL-2 in systemic lupus erythematosus, the potential synergistic effects of combining IL-2 administration with blockade of cytokine pathways that promote Tfh cell development and/or deplete B cells, and how more specifically target IL-2 to Tfh cells.



    Click here for a complete list of publications. Below are a few selected papers.

    Ballesteros-Tato A
    , Randall TD, Lund FE, Spolski R, Leonard WJ, León B. 2016. T Follicular Helper Cell Plasticity Shapes Pathogenic T Helper 2 Cell-Mediated Immunity to Inhaled House Dust Mite. Immunity. 44(2):259-73. PMID: 26825674; PMCID: PMC4758890.

    Leon, B., Bradley, J.E., Lund, F.E., Randall, T.D. & Ballesteros-Tato, A. 2014. FoxP3+ regulatory T cells promote influenza-specific Tfh responses by controlling IL-2 availability. Nature communications 5, 3495 PMID: 24633065 PMCID: PMC4013682

    Ballesteros-Tato, A.
    , Leon, B., Lund, F.E. & Randall, T.D. CD4+ T helper cells use CD154-CD40 interactions to counteract T reg cell-mediated suppression of CD8+ T cell responses to influenza. 2013 The Journal of Experimental Medicine 210, 1591-1601. PMID: 23835849 PMCID: PMC3727323

    Ballesteros-Tato, A, 
     León, B, Graf, BA, Moquin, A, Adams, PS, Lund, FE, Randal, TD. 2012 Interleukin-2 Inhibits Germinal Center Formation by Limiting T Follicular Helper Cell Differentiation.  Immunity. 36: 847-856. PMID:22464171

    Ballesteros-Tato, A
    , B León, FE. Lund and TD. Randall. 2010. Temporal changes in dendritic cell subsets, cross-priming and costimulation via CD70 control CD8+T cells responses to influenza. Nat. Immunol. 11:216-224. PMID:20098442 PMCID:PMC2822886

  • BennettUABPresidentDr. Bennett received his A.B. from Howard College (Samford University) in 1954, and his M.D. (cum laude) from Harvard Medical School in Boston, Massachusetts in 1958.  He served fellowships at the Massachusetts General Hospital (Rheumatology), the National Institutes of Health (Molecular biology) in Bethesda, Maryland and California Institute of Technology (Molecular Genetics) in Pasadena, California.He returned to Birmingham in 1965 to join the faculty at the University of Alabama at Birmingham (UAB).  From 1970-82, he was Professor and Chair of the Department of Microbiology and Director of the Division of Clinical Immunology and Rheumatology.  In 1982, he was named Professor and Chair of the Department of Medicine, and in 1992 was honored with the William and Evalina Spencer Chair in Medical Science Leadership.  On October 1, 1993, he became the fourth President of the University of Alabama at Birmingham.  In 1997, he was designated by the University Board of Trustees as Distinguished University Professor Emeritus and became President and Chief Operating Officer of BioCryst Pharmaceuticals, Inc. (1997-2008).

    Dr. Bennett has published over 200 scientific papers.  He has been Editor, Cecil Textbook of Medicine, 19th, 20th, and 21st editions (1998-2000); Editor-in-Chief of Arthritis and Rheumatism (1975-1980); Editor-in-Chief of the American Journal of Medicine (1986-97). 

    His contributions in research include the delineation of constant (C) and variable (V) regions of immunoglobulin molecules, based on peptide analyses of myeloma proteins.  These studies resulted in a general hypothesis for the generation of antibody diversity.  These studies also led to description of the phylogenetic development of the immune system and formed the basis for site attachment of complement in activation of the inflammatory pathway.  His clinical research focused on the structures of rheumatoid factors and relationships to various infectious agents as initiators of the rheumatoid process.

    He has received awards from a number of distinguished organizations including the Seale Harris Award, Southern Medical Association (1987); Master, American College of Physicians (1990); Phillips Memorial Award, American College of Physicians (1993); Robert H. Williams Distinguished Chair of Medicine Award, Association of Professors of Medicine (1994); Francis Gilman Blake Award, Association of American Physicians (1997); Master, American College of Rheumatology (1998); Carol Nachman Medal, German Society of Rheumatology (2000); and the Kober Medal from the Association of American Physicians (2000).  He has been awarded honorary degrees by the University of Alabama at Birmingham (D.Sc.1992), the University of Leipzig, Germany (Dr. Med [honoris causa] 1999), and the University of Zurich, Switzerland (Dr. Med [honoris causa] 2008).

    Dr. Bennett has been elected to membership in the American Academy of Microbiology, American Society for Clinical Investigation, the Association of American Physicians, the Institute of Medicine of the National Academy of Sciences, the American Academy of Arts and Sciences, and the Royal Society of Medicine, London, and an honorary member of the Ludwig Heilmeyer Society (Germany).

    His professional activities include President of the American College of Rheumatology (1981-1982); Chair, American Board of Internal Medicine (1994-1995); Chair, Board of Health Sciences Policy, Institute of Medicine, National Academy of Sciences (1988-1993); President, Association of Professors of Medicine (1991-1992); Chairman, Federated Council of Internal Medicine (1992-1993); NIH Director’s Panel on Clinical Research (1995-1998); President of the Association of American Physicians (1996-1997).

    Dr. Bennett has served on many scientific advisory boards, including the Scientific Advisory Committee for Massachusetts General Hospital (1983-1987; 2001-2005); Scientific Advisory Board Merck Sharp & Dohme Research Laboratories (1987-1989); Founding Board Deutsches RheumaForschungsZentrum, Berlin (1988-1998); Scientific Advisory Committee, Warren Alpert Foundation (1989-1997); Scientific Advisory Committee, Charles E. Culpepper Foundation, Inc. (1989-1995); Visiting Committee, Harvard Medical School (1992-1997); and Board of Governors of the Warren Grant Magnuson Clinical Center, at the National Institutes of Health (1996-1999).  


  • Beukelman mug 04 2014 1 crop

    Associate Professor, Division of Pediatric Rheumatology
    Department of Pediatrics

    Secondary Appointment: Division of Clinical Immunology & Rheumatology



    Children's Park Place North, Suite G10
    1601 4th Avenue South
    Birmingham, AL 35233-1711





    BS, University of Illinois, Urbana-Champaign, IL, 1997
    MD, Washington University, Saint Louis, MO, 2001
    Intern (Pediatrics): Cincinnati Children’s Hospital Medical Center, OH, 2002
    Resident (Pediatrics):Cincinnati Children’s Hospital Medical Center, OH, 2004
    Fellow (Pediatric Rheumatology):The Children’s Hospital of Philadelphia, PA, 2007
    M.S.C.E.,University of Pennsylvania, Philadelphia, PA, 2008


    Awards and Honors

    2013 ACR/EULAR International Academic Rheumatology Exchange, Early Career Investigator Delegate

    2013 Member, American Pediatric Society


    Research Description

    Dr. Beukelman’s research is focused on determining the safest and most effective treatments for juvenile idiopathic arthritis (JIA), the most common condition in pediatric rheumatology. He has authored or co-authored more than 60 peer-reviewed publications of original research, as well as several textbook chapters. Dr Beukelman was the lead investigator of the first American College of Rheumatology Recommendations for the Treatment of JIA. Dr Beukelman is the Scientific Director of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry, which was established to prospectively evaluate outcomes in the pediatric rheumatic diseases, including the safety and effectiveness of therapeutic agents. He has led several studies using administrative claims data to evaluate the associations between JIA and its treatment and the adverse events of serious infection and cancer.



    Click here for a complete list of publications in PubMed. A few selected papers are below

    Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, Patkar NM, Saag KG, Winthrop KL, Curtis JR. 2012. Rates of hospitalized bacterial infection in juvenile idiopathic arthritis and its treatment. Arthritis Rheum  64:2773-80. PMCID: 3409300

    Beukelman T, Haynes K, Curtis JR, Xie F, Chen L, Bemrich-Stolz CJ, Delzell E, Saag KG, Solomon DH, Lewis JD. 2012. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum  64:1263-7. PMCID: PMC3315602

    Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Martini A, Rabinovich CE, Ruperto N. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res  63:465-82. PMCID: PMC3222233



  • BradleyProfessor of Medicine


    Shelby Building Room 177A
    1825 University Blulevard

    Telephone:(205) 934-8550
    Fax:(205) 934-1564



    BA (Psychology), Vanderbilt University, 1971
    PhD (Clinical Psychology),Vanderbilt University, 1975
    Clinical Internship,Duke University Medical Center, 1975-1976


    Research Description

    Dr. Bradley's research focuses on the interactions among biological and psychosocial factors associated with abnormal pain sensitivity in persons with osteoarthritis (OA) of the knee, and other chronic painful disorders. Several studies are ongoing with support of an R01 grant and complementary grant funds: (1) In collaboration with investigators from the University of Florida, the goal of the R01 project is to characterize ethnic differences in experimental pain sensitivity, endogenous pain inhibition, clinical pain, and pain-related disability in older African-Americans and non-Hispanic whites with and without knee OA; (2) determine whether these measures of pain sensitivity/pain inhibition along with biological, psychological, and socio-cultural variables mediate ethnic group differences in clinical pain and pain-related disability; (3) examine the extent to which differences in pain responses between African-American and white patients with knee OA are mediated by group differences in biomarkers such as sleep disturbance or lipid mediators; and (4) examine the relationship between polysomnography measures of sleep and experimental as well as clinical pain to better understand the biological, psychological, and socio-cultural variables that mediate ethnic group differences in both sleep and pain.



    Click here for a complete list of publications. Below are a few selected papers

    Bulls HW, Goodin BR, McNew M, Gossett EW, Bradley LA. 2016. Minority aging and endogenous pain facilitatory processes. Pain Med 17: 1037-1048. PMCID: PMC4896853

    Herbert MS, Goodin BR, Bulls HW, Sotolongo A, Petrov ME, Edberg JC, Bradley LA, Fillingim RB. 2016.  Ethnicity, cortisol, and experimental pain responses among persons with symptomatic knee osteoarthritis. Clin J Pain. 2016 Nov 28. [Epub ahead of print] PMID: 27898457

    Cardoso JS, Riley JL 3rd, Glover T, Sibille KT, Bartley EJ, Goodin BR, Bulls HW, Herbert M, Addison AS, Staud R, Redden DT, Bradley LA, Fillingim RB, Cruz-Almeida Y. 2016 Experimental pain phenotyping in community-dwelling individuals with knee osteoarthritis. Pain. 157: 2104-2114. PMCID: PMC4988907

    Neogi T, Guermazi A, Roemer F, Nevitt MC, Scholz J, Arendt-Nielsen L, Woolf C, Niu J, Bradley LA, Quinn E, Law LF. 2016. Association of joint inflammation with pain sensitization in knee osteoarthritis: The Multicenter Osteoarthritis Study. Arthritis Rheumatol. 68: 654-661. PMCID: PMC4827020

    Petrov ME, Goodin BR, Cruz-Almeida Y, King C, Glover TL, Bulls HW, Herbert M, Sibille KT, Bartley EJ, Fessler BJ, Sotolongo A, Staud R, Redden D, Fillingim RB, Bradley LA. 2015. Disrupted sleep is associated with altered pain processing by sex and ethnicity in knee osteoarthritis. J Pain.  pii: S1526-5900(15)00541-6. PMID: 25725172

    Glover TL, Goodin BR, King CD, Sibille KT, Herbert MS, Sotolongo AS, Cruz-Almeida Y, Bartley EJ, Bulls HW, Horgas AL, Redden DT, Riley JL 3rd, Staud R, Fessler BJ, Bradley LA, Fillingim RB. 2015. A cross-sectional examination of Vitamin D, obesity, and measures of pain and function in middle-aged and older adults with knee osteoarthritis. Clin J Pain. 12: 1060 - 1067  PMID: 25569220

    Neogi T, Frey-Law L, Scholz J, Niu J, Arendt-Nielsen L, Woolf C, Nevitt M, Bradley L, Felson DT, for the Multicenter Osteoarthritis (MOST) Study. 2015. Sensitivity and sensitisation in relation to pain severity in knee osteoarthritis: trait or state? Ann Rheum Dis 74: 682-688. PMID: 24351516 PMCID:PMC4062615

    Glass N, Segal NA, Sluka KA, Torner JC, Nevitt MC, Felson DT, Bradley LA, Neogi T, Lewis CE, Frey-Law LA. 2014. Examining sex differences in knee pain: the Multicenter Osteoarthritis Study. Osteoarthritis Cartilage. 22(8):1100-6. PMID: 24999111 PMCID: PMC4180745

    Petrov ME, Sawyer P, Kennedy R, Bradley LA, Allman RM. 2014. Benzodiazepine (BZD) use in community-dwelling older adults: Longitudinal associations with mobility, functioning, and pain. Arch Gerontol Geriatr. 59(2):331-7. PMID: 24880195 PMCID: PMC4130769

    Cruz-Almeida Y, Sibille KT, Goodin BR, Petrov ME, Bartley EJ, Riley JL, King CD, Glover TL, Sotolongo A, Herbert MS, Schmidt J, Fessler BJ, Staud R, Redden D, Bradley LA, Fillingim RB. 2014. Racial and ethnic differences in older adults with knee osteoarthritis. Arthritis Rheum 66:1800-1810 PMID: 24729357 PMCID: PMC4077911

    Goodin BR, Bulls HW, Herbert MS, Schmidt J, King CD, Glover TL, Sotolongo A, Sibille KT, Cruz-Almeida Y, Staud R, Fessler BJ, Redden DT, Bradley LA, Fillingim RB. 2014. Temporal summation of pain as a prospective predictor of clinical pain severity in adults aged 45 years and older with knee osteoarthritis: ethnic differences. Psychosom Med. 76(4):302-10. PMID: 24804882 PMCID: PMC4066647

    Riley III JL, Cruz-Almeida Y, Glover TL, King CD, Goodin BR, Sibille KT, Bartley EJ, Herbert MS, Sotolongo A, Fessler BJ, Redden DT, Staud R, Bradley LA, Fillingim RB. 2014. Age and race effects on pain sensitivity and modulation among middle-aged and older adults. J Pain 15: 272–282 PMCID: PMC4005289

    Ruiter Petrov ME, Lichstein KL, Huisingh CE, Bradley LA. 2014. Predictors of adherence to a brief behavioral insomnia intervention: daily process analysis. Behav Ther. 45(3):430-42. PMID: 24680236

    Herbert MS, Goodin BR, Pero ST 4th, Schmidt JK, Sotolongo A, Bulls HW, Glover TL, King CD, Sibille KT, Cruz-Almeida Y, Staud R, Fessler BJ, Bradley LA, Fillingim RB. 2014. Pain hypervigilance is associated with greater clinical pain severity and enhanced experimental pain sensitivity among adults with symptomatic knee osteoarthritis. Ann Behav Med. 48(1):50-60. PMID: 24352850  PMCID: PMC 4063898

    King CD, Sibille KT, Goodin BR, Cruz-Almeida Y, Glover TL, Bartley E, Riley JL,Herbert MS, Sotolongo A, Schmidt J, Fessler BJ, Redden DT, Staud R, Bradley LA, Fillingim RB. 2013. Experimental pain sensitivity differs as a function of clinical pain severity in symptomatic knee osteoarthritis. Osteoarthritis Cartilage 21: 1243-1252 PMCID: PMC3831366

    Goodin BR, Pham Q, Glover T, King C, Sibille KT, Cruz-Almeida Y, Staud R, Redden D, Bradley LA, Fillingim R. 2013. Perceived racial discrimination, but not mistrust of medical researchers, predicts the heat pain tolerance of African Americans with symptomatic knee osteoarthritis. Health Psychology, 32: 1117-1126. PMCID: PMC3943939

    Goodin BR, Glover TL, Sotolongo A, King CD, Sibille KT, Herbert MS, Cruz-Almeida Y, Sanden SH, Staud R, Redden DT, Bradley LA, Fillingim RB. 2013. The association of greater dispositional optimism with less endogenous pain facilitation is indirectly transmitted through lower levels of pain catastrophizing. J Pain. 14(2):126-35. PMCID: PMC3592576

    Herbert MS, Varley AL, Andreae SJ, Goodin BR, Bradley LA, Safford MM. 2013. The association of pain and HbA1c in a predominantly black sample of community-dwelling adults with diabetes: a cross-sectional analysis. Diabetic Med 30: 1466-1471 PMCID: PMC3935766

    Cruz-Almeida Y, King CD, Goodin BR, Sibille KT, Glover TL, Riley JL, Sotolongo A, Herbert MS, Schmidt J, Fessler BJ, Redden DT, Staud R, Bradley LA, Fillingim RB. 2013. Psychological profiles and pain characteristics of older adults with knee osteoarthritis. Arthritis Rheum (Arthritis Care Res)  65: 1786-1794 PMCID: PMC3922880


  • Bridges LouAnna Lois WatersEndowed Chair, Division of Clinical Immunology and Rheumatology
    Professor of Medicine
    Director, Division of Clinical Immunology & Rheumatology


    Shelby Building, Room 178C
    1825 University Boulevard

    Administrative Associate: Paula Kiley
    Shelby Building, Room 178B
    1825 University Blvd.
    Birmingham, AL35294-2182
    Fax: 205-934-1564
    Email: pfkiley@uabmc.edu 



    BS, Preprofessional Studies, University of Notre Dame, 1980
    MD,Louisiana State University School of Medicine, 1984
    PhD, University of Alabama at Birmingham, 1995
    Internship and Residency,Internal Medicine, University of Texas Medical Branch, Galveston 1984-1987
    Chief Residency, Internal Medicine, University of Texas Medical Branch, Galveston 1987-1988
    Fellowship, Clinical Immunology and Rheumatology, University of Alabama at Birmingham, 1988-1991


    Research Team

    Stephanie S. Ledbetter, MS Program Manager
    Keith Wanzeck   Lab Manager
    Jinyi Wang Research Associate
    Selena D. Luckett-Smith, RN Study Coordinator
    Laticia Woodruff, RN Study Coordinator
    Dongmei Sun, PhD Database Manager
    Vincent Laufer MD/PhD Student



    Research Description and Potential Projects for Trainees

    My earliest research interest, the role of B lymphocytes and autoantibodies in rheumatoid arthritis (RA), particularly immunoglobulin gene expression and antibody repertoires in synovial tissue, formed the basis of my PhD studies. In addition, my research has focused on identification of genetic influences on RA susceptibility and severity, particularly in African-Americans, and on autoantibodies and biomarkers of treatment response in RA. I have led several multicenter consortia, including the Consortium for the Longitudinal Evaluation of African-Americans with Rheumatoid Arthritis (CLEAR) Registry and Repository; the Biorepository of the Treatment of Early Aggressive RA (TEAR) Trial; and the Treatment Efficacy and Toxicity in RA Database and Repository (TETRAD).



    Click here for a complete list of publications in PubMed.


    Active Research Projects


    Multidisciplinary Clinical Research Center

    As Director of UAB's Multidisciplinary Clinical Research Center (MCRC), funded by NIH P60 AR064172, I oversee a multidisciplinary program to promote research related to the causes, diagnoses, treatments and improved care of patients with arthritis and musculoskeletal diseases. The MCRC contains an Administrative Core, a Methodology Core (led by Xiangqin Cui, PhD, and David Redden, PhD of the UAB Department of Biostatistics, SOPH) and two research projects (see below).

    The mission of the MCRC Methodology Core is to develop and provide state of the art methodology and methodological education in the collaborative support of clinical and translational research in arthritis and musculoskeletal disease (MSD) at the local, regional, national, and international level. Toward this goal, the Core will continue to provide the statistical, epidemiological, outcomes research, statistical genetics, economics/cost effectiveness and bioinformatics leadership and expertise required to develop and perform cutting edge clinical research in arthritis and MSD it pursues four broad goals:

    • To support the design, data collection, management and analytic efforts of the MCRC projects
    • To nurture original research in methodology applicable to clinical research in arthritis and MSD
    • To develop new investigators in the area of arthritis and MSD research
    • To provide methodology seminars, workshops and mini-courses to introduce the newest methodological approaches to the MCRC research base.

    MCRC Project 1. Facilitating Treat-to-Target Strategies Using Novel Health Technology with Decision Support (PI: Jeffrey R. Curtis, MD, MS, MPH). This project will extend and evaluate novel health information technology to enable the systematic collection and integration of Patient Reported Outcome (PRO) and healthcare provider data in routine clinical practice; make use of this data to facilitate patient-provider interaction around optimal use of rheumatoid arthritis (RA) therapies; integrate this data with information in Electronic Health Record (EHR) systems; and demonstrate benefit for both process and outcomes among patients with RA.

    MCRC Project 2. Adaptive Immune Responses to Gut Microbiota in Juvenile and Adult Spondyloarthritis (PI: Charles O. Elson, MD, and Co-PI: Matthew Stoll, MD, PhD, MSCS). This project will integrate cutting-edge technologies of antigen identification with microbiome/metagenome analysis to provide novel information on the microbial contributions to spondyloarthritis. The data will result in new insights into the pathogenesis of SpA, suggest potential new biomarkers for diagnosis and monitoring, and lead to new approaches to therapy by manipulating the microbiota and adaptive immune responses to it.


    Center of Research Translation (CORT) in Gout and Hyperuricemia

    As Co-Director of the UAB CORT in Gout and Hyperuricemia (NIH P50 AR060772 - KG Saag, Contact PI; SL Bridges, Jr., PI), I am involved in three research projects focused on characterizing biomarkers of inflammation (CRP), vascular disease (endothelial function), and blood pressure changes associated with allopurinol (Project 1); examining factors associated with suboptimal gout care and factors influencing effective and safer dosing of allopurinol and colchicine in African-Americans and Caucasians (Project 2); and comparing the effectiveness of a novel pharmacy-based "virtual" Gout Clinic that includes protocol-driven care to usual care in the treatment of chronic gout (Project 3). The overall goal of our CORT (K. Saag, Director) is to improve the health of patients with gout and hyperuricemia by applying scientifically rigorous, state-of-the-art methodology to clinically important questions in translational investigation and to educate clinical investigators through an enrichment program. These innovative projects hold the promise of significant improvements in our understanding of the pathogenesis of gout and related co-morbid conditions, and may ultimately lead to better ways to predict, treat, or prevent gout and hyperuricemia.


    Rheumatic Disease Cores Center

    As Associate Director of the UAB Rheumatic Disease Cores Center (RDCC) (NIH P30 AR048311, John D Mountz, MD, PhD, PI and Director), I serve as collaborate with Dr. Mountz to provide assistance in the strategic planning, management and evaluation functions of the RDCC; and have primary responsibility for the development of Scientific Programs & Career Development program and for the management and monitoring the progress of the Pilot & Feasibility (P&F) Program. The RDCC consists of UAB investigators pursuing research in the rheumatic diseases, the Administrative Core, and three Research Cores: Comprehensive Flow Cytometry Core (CFCC); Analytical Imaging and Immunoreagent Core (AIIC); and Analytical Genomics and Transgenics Core (AGTC).


    VERVE Trial

    I serve as investigator and Director of the Biorepository for the Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (Varicella zostER VaccinE [VERVE]) trial, a randomized, double-blind, placebo-controlled large pragmatic trial to evaluate the immunogenicity, safety, and longer-term effectiveness of the live HZ vaccine in arthritis patients receiving anti-TNF therapy (UM1 AR065705 - JR Curtis, PI).


    TWEAK Trial

    A more recent interest is in mechanisms of muscle inflammation and it impact on mobility after joint replacement for arthritis. Though R01 HD084124 Overcoming TWEAK Signaling to Restore Muscle and Mobility after Joint Replacement (M Bamman, Contact PI/SL Bridges, Jr., MPI), we will test the hypothesis that progressive resistance exercise training plus adjunctive functional mobility training after total hip or knee arthroplasty will more effectively restore muscle mass and mobility function to healthy standards than usual care, particularly in patients with TWEAK (TNF-like weak inducer of apoptosis)-mediated muscle inflammation. We will perform a randomized controlled trial of THA/TKA patients to test this hypothesis and study the cellular and molecular mechanisms of muscle mass regulation.


    National Resource Center for High-Impact Clinical Trials in Medical Rehabilitation

    Our NIH-funded P2C National Resource Center for High-Impact Clinical Trials in Medical Rehabilitation (High-Impact Trials Center, HITC) will serve as a catalyst for the design and implementation of rigorous, high-impact clinical trials to advance medical rehabilitation research. Oversight of the Center is provided by Marcas Bamman, PhD (Director). I serve on the Executive Committee and as Director of the HITC Pilot Component (Pilot-C). The goal of this component is to catalyze the success of medical rehabilitation researchers and interdisciplinary teams by providing consultation, seed funds, key expertise and resources, and ultimately feedback, to medical rehabilitation researchers for the conduct of innovative pilot projects, early-stage proof-of-concept studies, and futility studies needed to shape more definitive clinical trials. The central goal will be met by achieving the following aims: Aim 1. To work closely with the Collaborative Component, providing consultation to medical rehabilitation research teams on how to: 1) Formulate and refine strong and impactful research questions; 2) Identify the goals and aims needed to achieve future clinical outcome trials. Aim 2. To identify and prioritize the most competitive proposals for both pilot studies and voucher funding via an annual peer review process. Aim 3. To provide expertise, resources, and/or mentorship to selected pilot study awardees with ongoing availability during the planning and implementation phases in order to: 1) Bolster the scientific yield of each pilot study; and 2) Position each awardee for a subsequent, highly competitive clinical trial application. Aim 4. To provide constructive and substantive feedback to applicants not selected for funding, and to direct those applicants toward other programs and opportunities within the Center that can strengthen future applications. The Pilot-C will award four $40K pilot studies per year.


    The Rheumatoid Arthritis Synovial Tissue Network

    I served as site PI of the Rheumatoid Arthritis Synovial Tissue Network (REASON) Study (UH2 AR067687 - RM Pope, Northwestern Univ). The goals of this study are to create a new generation of rheumatologists in the United States who will perform minimally invasive ultrasound guided synovial biopsies that is critical for obtaining of synovial tissue from patients at all phases of RA (early, established, DMARD or biologic inadequate response). We have assembled a consortium of leading academic rheumatology groups which includes UAB, Columbia University, Mayo Clinic, Washington University, University of Michigan, and Northwestern University to obtain synovial tissue from RA patients for translational studies to identify novel pathways and potential biomarkers that might predict therapeutic response. We anticipate that we will be part of the NIH Accelerating Medicines Partnership to provide training for synovial biopsy, as well as RA synovial tissue samples to the collaborative research network.


  • ChathamProfessor of Medicine
    Louis W. Heck Clinical Scholar
    Clinical Director, Division of Clinical Immunology & Rheumatology



    Faculty Office Tower (FOT), Room 858
    510 20th Street South

    Telephone:(205) 996-5602



    BSE, Biomedical Engineering, Duke University, 1976
    MD,Vanderbilt University, 1980
    Internship and Residency,Internal Medicine, University of North Carolina Hospital, Chapel Hill, NC, 1980-1983
    Fellowship,Rheumatology, University of Alabama at Birmingham, 1986-1989


    Clinical Interests

    • Lupus
    • Immunodeficiency-associated rheumatic disease
    • Sarcoidosis
    • Auto-inflammatory and macrophage activation syndromes


    Research Description

    Dr. Chatham's research program is focused on the biology of TNF family receptors and their ligands (including BLyS/BAFF) as these relate to disease expression in lupus and other inflammatory/autoimmune disorders. The therapeutic implication of these studies has been extended to current clinical studies that involve the use of monoclonal reagents and soluble receptors targeting BlyS/BAFF in patients with active systemic  lupus as well as their potential use in autoimmunity associated with immunodeficiency. Additional collaborative studies are examining the biology of type-1 interferons and  interferon-alpha blocking reagents on disease activity in systemic lupus and macrophage activation disorders.



    Click here for a more complete list of publications. Below are a few selected papers.

    Chatham W, Chadha A, Fettiplace J, Kleoudis C, Bass D, Roth D, Gordon D.2017. A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus. Lupus. 2017, Jan 1 [Epub ahead of print] PMID: 28467293

    Cron RQ, Chatham WW. 2016. Development of spondyloarthropathy following episodes of macrophage activation syndrome in children with heterozygous mutations in haemophagocytic lymphohistiocytosis-associated genes. Clin Exp Rheumatol. 34(5):953. PMID: 27383696

    Zhang M, Bracaglia C, Prencipe G, Bemrich-Stolz CJ, Beukelman T, Dimmitt RA, Chatham WW, Zhang K, Li H, Walter MR, De Benedetti F, Grom AA, Cron RQ. 2016. A Heterozygous RAB27A Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic Lymphohistiocytosis.J Immunol. 196(6):2492-503 PMC4779709

    Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, Aranow C, Wellborne FR, Abud-Mendoza C, Hough DR, Pineda L, Migone TS, Zhong ZJ, Freimuth WW, Chatham WW; BLISS-52 Study Group; BLISS-76 Study Group. 2012. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 64(7):2328-37. PMID:22275291 PMCID:PMC3350827

    Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF; BLISS-76 Study Group. 2011. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63(12):3918-30. PMID:22127708



  • Curtis2013Harbert Ball Endowed Chair Professor 
    Director, UAB Arthritis Clinical Intervention Program
    Co-Director, UAB Center for Education and Research on Therapeutics (CERTS) of Musculoskeletal Disorders
    Co-Director, UAB PharmacoEpidEmiology and phaRmcoeconomics (PEER) Unit
    University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology



    Faculty Offices Tower, room 802
    510 20th Street South
    Birmingham, AL 35294

    Telephone:(205) 975-2176



    BS (Biology),University of California at San Diego
    MD,Oregon Health & Sciences University, Portland, OR
    MPH,Oregon Health & Sciences University, Portland, OR
    Residency (Internal Medicine):Oregon Health & Science University
    Fellowship (Clinical Immunology and Rheumatology): University of Alabama at Birmingham
    MS (Epidemiology), Harvard School of Public Health
    Postdoctoral (Clinical Informatics):Stanford University


    Research and Clinical Interests

    Dr. Jeffrey Curtis is a Professor of Medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham (UAB). Dr. Curtis received a Medical Degree (MD) and a Master of Public Health (MPH) degree from Oregon Health & Sciences University in Portland, OR. He subsequently completed a residency in internal medicine at Oregon Health & Science University and a fellowship in rheumatology at UAB. He completed a graduate program in Clinical Informatics at Stanford University and received his Master of Science (MS) degree in epidemiology at the Harvard School of Public Health. He is board certified in both rheumatology and clinical informatics.

    Dr. Curtis currently holds the William J. Koopman Endowed Professorship in Rheumatology and Immunology at UAB. He is the Co-Director of the UAB Center for Education and Research on Therapeutics (CERTs) of Musculoskeletal Disorders, which has a major emphasis on evaluating the safety and comparative effectiveness of medications for rheumatic diseases. Additionally, as the Director of the UAB Arthritis Clinical Intervention Program, he leads the clinical trials unit for the rheumatology division at UAB, with a particular focus on rheumatoid arthritis (RA) and psoriatic arthritis (PsA). He is the Co-Director of the UAB Pharmacoepidemiology and Pharmacoeconomics Research (PEER) Unit. PEER uses multiple large data sources to study comparative effectiveness questions across multiple chronic diseases. These data sources include national administrative data from Medicare and commercial health plans, electronic health record data, and large registries. In 2012, he was awarded the Henry Kunkel Young Investigator Award by the American College of Rheumatology (ACR) and was accepted into the American Society for Clinical Investigation (ASCI) in 2016.

    The evaluation of the efficacy, comparative effectiveness, and safety of the medications used to treat rheumatoid arthritis and spondyloarthritis are among Dr. Curtis’s research interests. He served on the Core Expert Panel for the ACR’s 2008, 2012, and 2015 Recommendations for the Use of Nonbiologic and Biologic Disease Modifying Antirheumatic Drugs in RA. He was the Deputy Director for a collaborative project between the FDA, the Agency for Healthcare Research and Quality (AHRQ), and a number of academic centers studying the safety of biologic agents using multiple, pooled national data sources. He is the Co-PI of the PCORI-funded Patient Powered Research Network “Arthritis-Power” registry, focused on RA, psoriasis, and psoriatic arthritis. He also leads the multi-center NIH-funded large pragmatic randomized controlled trial “VERVE” studying the safety and effectiveness of the live herpes zoster vaccine in patients receiving biologic agents. He is a member of the Center for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) Herpes Zoster workgroup. In 2015, he was appointed as a member to the FDA Arthritis Advisory Committee.

    Dr. Curtis also studies risk factors for and outcomes of osteoporosis. He was a member of the ACR’s task force to update recommendations for the management of glucocorticoid induced osteoporosis (GIOP). He served on the ASBMR Task Force on Atypical Subtrochanteric and Diaphyseal Fractures.

    Dr. Curtis is a member of the American College of Rheumatology (ACR), the International Society for Pharmacoepidemiology (ISPE), the American Medical Informatics Association (AMIA), and the American Society of Bone and Mineral Research (ASBMR). He has been on the editorial board for Arthritis & Rheumatism, Pharmacoepidemiology and Drug Safety (PDS) and Arthritis Care and Research (AC&R). He has authored more than 350 peer-reviewed manuscripts, review articles and book chapters.



    Click here for a complete list of publications. Below are a few selected papers.

    Curtis JR, McVie T, Mikuls T, Reynolds, RJ, Navarro I, O’Dell J, Moreland L, Bridges SL, Ranganath, VK, Cofield SS. 2013. Clinical Response with 12 Weeks as a Predictor of Future Low Disease Activity in Early Rheumatoid Arthritis Patients: Results from the TEAR Trial. Journal of Rheumatology. PMID 23588939; PMC 3694569

    Curtis JR, Xie F, Chen L, Muntner P, Grijalva CG, Spettell C, Fernandes J, McMahan RM, Baddley JW, Saag KG, Beukelman T, Delzell E. 2012. Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 64(10):1480-9. PMID: 22833479 PMC3687540

    Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, Saag KG, Baddley JW, Curtis JR. 2012. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 308(1):43-9. PMID: 22760290

    Curtis JR, van der Helm-van Mil AH, Knevel R, Huizinga TW, Haney DJ, Shen Y, Ramanujan S, Cavet G, Centola M, Hesterberg LK, Chernoff D, Ford K, Shadick NA, Hamburger M, Fleischmann R, Keystone E, Weinblatt ME. 2012. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). 64(12):1794-803. PMID: 22736476

    Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, Griffin MR, Herrinton LJ, Liu L, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Lewis JD, Xie F, Saag KG, Curtis JR. 2011. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 306(21):2331-9. PMC3428224



  • Danila 2017Associate Professor of Medicine
    Ambulatory Clinical Director, Rheumatology


    Faculty Office Tower, room 838
    510 20th Street South, Birmingham, AL 35294-3408

    Patient care telephone: (205) 996-7438
    Patient care fax: (205) 583-8060
    Email: mdanila@uab.edu

    Administrative Assistant:
    Patricia Taylor
    Telephone: (205) 996-5602
    Fax: (205) 934-4198


    MD,“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
    Internship (General Medicine),“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
    MSc (Microbiology),University of Victoria, Victoria, BC, Canada
    Residency in Internal Medicine,University of Illinois at Chicago-Advocate Christ Medical Center, Oak Lawn, IL
    Clinical Rheumatology Fellow, University of Alabama at Birmingham
    MSPH (Epidemiology), School of Public Health, University of Alabama at Birmingham
    Graduate Certificate in Health Quality and Safety, School of Health Professions, University of Alabama at Birmingham

    Clinical Interests

    • Rheumatoid Arthritis
    • Connective tissue associated interstitial lung disease
    • Sjogren's syndrome
    • Scleroderma


    Research Interests

    Dr. Danila is an Associate Professor of Medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham (UAB). Dr. Danila is an implementation scientist and outcome researcher, passionate about improving the quality, effectiveness and processes/delivery of medical care for patients. Her research program focuses on two main areas: i) the design and evaluation of culturally-adapted and literacy-appropriate health care interventions that improve outcomes for patients with chronic conditions; and ii) the development and implementation of strategies to assist physicians and other health care professionals in engaging in shared decision making and evidence-based clinical practice.

    Dr. Danila is also interested in the redesign of healthcare delivery processes, decreasing healthcare costs and increasing value-based medical care. She has been actively involved as volunteer for the American College of Rheumatology (ACR). She served on the ACR Insurance Subcommittee (ISC) from 2012-2016.



    Click here for a list of publications.


  • jeffrey_edbergProfessor of Medicine
    Co-Director, Participant & Clinical Interactions Resources (PCIR)



    Shelby Building, Room 207
    1825 University Boulevard

    Telephone:(205) 934-0894
    Email: jedberg@uab.edu



    BS (Chemistry), University of Illinois, 1986
    PhD, University of Virginia, 1990
    Post-Doctoral Training, Cornell University medical College, 1988-1991


    Research Description

    Wegener's granulomatosis, an anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic small vessel vasculitide, is characterized by inflammatory lesions with granuloma formation in the upper and lower airways, pauci-immune glomerulonephritis, and anti-proteinase 3 autoantibodies. Although Wegener's granulomatosis is considered idiopathic, there has been substantial interest in environmental factors as either etiologic or accelerating risk factors, with Staphylococcus aureus having attracted substantial attention as one such environmental factor. Although consensus about etiology remains elusive, the nature of the host response has emerged as an important determinant for disease phenotype and severity. Although Wegener's granulomatosis occurs sporadically, and does not show classical familial clustering and transmission characteristic of some autoimmune diseases, the identification of important genetic factors in Wegener's granulomatosis is not only feasible but also potentially very fruitful in providing insights into pathogenesis and potential therapeutic targets. Building on the clinical trial of etanercept in Wegener's granulomatosis, Dr. Edberg, in collaboration with Drs. Kimberly and Kaslow, is developing a renewable genetic repository to explore the relationship between the Wegener's granulomatosis diathesis and genetic polymorphisms in candidate molecules, selected for their role in pathophysiology. These studies also will involve identification of new polymorphisms in such molecules and application of these to this cohort.



    Click here for a more complete list of publications. Below are a few selected papers.

    Li X, Baskin JG, Mangan EK, Su K, Gibson AW, Ji C, Edberg JC, Kimberly RP. The unique cytoplasmic domain of human FcγRIIIA regulates receptor-mediated function. 2012. J Immunol. 189(9):4284-94. PMID:23024279

    Kelley JM, Monach PA, Ji C, Zhou Y, Wu J, Tanaka S, Mahr AD, Johnson S, McAlear C, Cuthbertson D, Carette S, Davis JC Jr, Dellaripa PF, Hoffman GS, Khalidi N, Langford CA, Seo P, St Clair EW, Specks U, Stone JH, Spiera RF, Ytterberg SR, Merkel PA, Edberg JC, Kimberly RP. 2011. IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. Proc Natl Acad Sci U S A. 108(51):20736-41. PMID:22147912

    Perkins EA, Landis D, Causey ZL, Edberg Y, Reynolds RJ, Hughes LB, Gregersen PK, Kimberly RP, Edberg JC, Bridges SL Jr; Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis Investigators. 2012. Association of single-nucleotide polymorphisms in CCR6, TAGAP, and TNFAIP3 with rheumatoid arthritis in African Americans. Arthritis Rheum. 64(5):1355-8. PMID:22127930

    Tan W, Sunahori K, Zhao J, Deng Y, Kaufman KM, Kelly JA, Langefeld CD, Williams AH, Comeau ME, Ziegler JT, Marion MC, Bae SC, Hyun Lee J, Lee JS, Chang DM, Wook Song Y, Yu CY, Kimberly RP, Edberg JC, Brown EE, Petri MA, Ramsey-Goldman R, Vilá LM, Reveille JD, Alarcón-Riquelme ME, Harley JB, Boackle SA, Stevens AM, Hal Scofield R, Merrill JT, Freedman BI, Anaya JM, Criswell LA, Jacob CO, Vyse TJ, Niewold TB, Gaffney PM, Moser KL, Gilkeson GS, Kamen DL, James JA, Grossman JM, Hahn BH, Tsokos GC, Tsao BP; on behalf of the BIOLUPUS GENLES networks. 2011. Association of PPP2CA polymorphisms with SLE susceptibility in multiple ethnic groups. Arthritis Rheum.  63(9):2755-63 PMID: 21590681


  • Elgavish2rev2Associate Professor of Medicine
    Program Manager, Program in Immunology


    Shelby Building, Room 415
    1825 University Boulevard

    Telephone:(205) 934-6547



    BS, Tel Aviv University, Tel Aviv, Israel
    MSc,Tel Aviv University, Tel Aviv, Israel
    PhD, Wezimann Institute of Science, Rehovoth, Israel
    Fogarty Visiting Fellow, Laboratory of Membrane Biology, NIH



    Fogarty Fellowship, NIH, 1979-1981

    American Lung Association, Career Investigator Award, 1987-1992


    Research Interests

    My main scientific interests have been in the biology of the genitourinary tract. Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC) is a chronic inflammatory disease of the bladder wall. More than 100 years after first being described, the diagnosis of BPS/IC is still associated with controversy. Given the difficulties associated with the diagnosis of BPS/IC, it is not surprising that the etiology of this syndrome is poorly understood. Several theories for the etiology of BPS/IC have been proposed over the years including infection, immunological etiology, leaky urothelium resulting from a deficiency of its surface coat of glycosaminoglycans, activated mast cells and neural changes.

    In vitro studies in my laboratory have been consistent with the possibility that BPS/IC may develop in response to noxious stimuli in the bladder lumen. Thus, lipoteichoic acid (LT-2), a cell wall component of the gram-positive bacterium Streptococcus faecalis, stimulated the proliferation rate of a subpopulation of basal uroepithelial cells with high proliferative potential (possibly stem cells). their progeny differentiated at a higher rate and displayed abnormal expression and cellular distribution of β1 integrins, and LT-2 required activation of iNOS and NFκB. Moreover, our studies provided evidence for altered proliferative ability of progenitors of urothelial cells in cell cultures isolated from patients with BPS/IC. These studies raised a number of questions: What are the mechanisms by which noxious stimuli in the bladder lumen may trigger abnormal function of the muscle and nerve tissue underlying the uroepithelium, causing pain and persistent urge to void? In addition, how is it possible that chronic symptoms similar to those characteristic of bacterial cystitis persist for years in patients with BPS/IC in whom no infectious agent is detected at the time of diagnosis? Based on emerging data from several laboratories, I postulated in a recent review that epigenetic reprogramming mechanisms in the bladder may provide an explanation for uroepithelial, mast cells and nerve cell abnormalities in BPS/IC, as well as propagation of this altered state in the absence of the signal that may have triggered it. Data supporting this hypothesis would provide a rationale for new diagnostic, treatment and dietary intervention options for BPS/IC.

    My second scientific interest is dietary prevention of prostate cancer (PC). PC is the most commonly diagnosed cancer in North American men. Findings of latent or clinically insignificant PC occurs in a large proportion, and at equal rates, in autopsy studies among men from Asian countries and the United States. In contrast, the incidence of clinically significant PC is an order of magnitude higher in the United States. Epidemiological studies suggest that this might be attributable to differences in environmental factors and life style, including nutrition. Aggressive PC is less prevalent among Asian men where the intake of soy products is very high. However, with Westernization and loss of traditional eating habits, the pattern of disease incidence is also changing in Asian men. On the basis of these findings, it has been postulated that phytoestrogens, including genistein, may have a preventive role in PC. Studies in my laboratory in a transgenic mouse model of prostate cancer (TRAMP mice), supported this hypothesis

    Prostate cancer fatalities are rarely due to primary tumors, but rather to widespread metastatic disease. The preferential colonization of bone by prostatic adenocarcinomas has been attributed to the passage of prostate epithelial cells from the prostate to the spine via paravertebral blood vessels. However, molecular mechanisms that facilitate retention of metastatic cells in bone and, their subsequent unrestricted proliferation, are poorly understood. In my laboratory, in vitro studies in cell cultures isolated from the human prostate and in vivo studies in the  transgenic mouse model of prostate cancer focused on cell adhesion-mediated molecular mechanisms that: (i) May underlie progression of slow growing prostate tumors to metastatic growth; and that (ii) May be the target of preventive strategies that delay progression of indolent prostate tumors to metastatic growth.

    More recent collaborative studies with Gabriel A. Elgavish were focused on developing an MRI method for early noninvasive detection of developing PC.

    In the past few years, in collaborative studies with Harry W. Schroeder, Jr., my interests have expanded to the link between natural protection, e.g., against pneumococci, and D(H) gene conservation.



    Click here for a complete list of publications. Below are a few selected papers

    Mohamed Khass, Robert L. Schelonka, Cun Ren Liu, Ada Elgavish, Laurence Morel, Peter D. Burrows, Harry W. Schroeder, Jr. 2017. Alterations in B cell development, CDR-H3 repertoire and dsDNA-binding antibody production among C57BL/6 ΔD−iD mice congenic for the lupus susceptibility loci sle1, sle2 or sle3. Autoimmunity 50: 42-51.

    Wang Y, Hwangpo T, Martin MP, Vince N, Qi Y, Reynolds RJ 4th, Absher D, Gao X, Ballinger CA, Burrows PD, Atkinson TP, Brown EE, Elgavish A, Liu C, Carrington M, Schroeder HW. 2016. Killer cell immunoglobulin-like receptors are associated with common variable immune deficiency pathogenesis. J Allergy Clin Immunol. 138(5):1495-1498. PMID: 27665490

    Yuge Wang, Pratibha Kapoor, Robert Parks, Aaron Silva-Sanchez, S. Munir Alam, Laurent Verkoczy, Hua-Xin Liao, Yingxin Zhuang, Peter Burrows, Michael Levinson, Ada Elgavish, Xiangqin Cui, Barton F. Haynes and Harry Schroeder Jr. 2016. HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence. Immunogenetics. 68(2):145-55. PMID: 26687685 PMCID: PMC4729650

    Silva-Sanchez A, Liu CR, Vale AM, Khass M, Kapoor P, Elgavish A, Ivanov II, Ippolito GC, Schelonka RL, Schoeb TR, Burrows PD, Schroeder HW Jr. 2015. Violation of an Evolutionarily Conserved Immunoglobulin Diversity Gene Sequence Preference Promotes Production of dsDNA-Specific IgG Antibodies. PLoS One. 10(2):e0118171. PMID: 25706374 PMCID: PMC4338297

    Vale AM, Kapoor P, Skibinski GA, Elgavish A, Mahmoud TI, Zemlin C, Zemlin M, Burrows PD, Nobrega A, Kearney JF, Briles DE, Schroeder HW Jr. 2013. The link between antibodies to OxLDL and natural protection against pneumococci depends on D(H) gene conservation. J Exp Med. 210(5):875-90. PMID: 23589567 PMCID: PMC3646500

  • FineProfessor Emeritus of Medicine
    Founder and Director Emeritus,UAB Injury Control Research Center

    Founder and Director Emeritus,The Southern Consortium for Injury Biomechanics
    Founder and Director Emeritus,The UAB University Transportation Related Injury Center


    Dr. Philip R. (Russ) Fine, an injury epidemiologist/biostatistician by training, is the founding director and former Director and Principal Investigator of the University of Alabama at Birmingham’s Injury Control Research Center (UAB ICRC), the Southern Consortium for Injury Biomechanics, and, the UAB University Transportation Related Injury Center.

    Dr. Fine is a graduate of Southern Illinois University, the University of Missouri Medical Center at Columbia, from where he received the MSPH degree, and the University of Oklahoma Medical Center at Oklahoma City, from where he received his PhD.

    He has experience in many areas of public health and injury control, from investigating commercial and private aviation crash events for the Federal Aviation Administration; as Director of Research for the Chicago Board of Health; to establishing and directing the Illinois Department of Public Health’s Statewide Pediatric Lead Poisoning Program from his position as Health Services Coordinator during the administration of the late Governor, Richard B. Ogilvie between 1968 and 1972.  Subsequently, Dr. Fine spent three years in the private sector as Executive Vice President of Mediclinic Corporation, MasterCare Health Plan and The Chicago Loop Mediclinic, Illinois’ first outpatient surgical center.

    Dr. Fine joined UAB’s Department of Rehabilitation Medicine in early 1975 where he achieved the rank of full tenured professor in 1983. While with the Department of Rehabilitation Medicine he served as its Director of Research and Scientific Affairs, Director of Research for the NIDRR-sponsored Medical Rehabilitation Research and Training Center in Spinal Cord Dysfunction, Co-Director of the UAB Spinal Cord Injury Care System, and Co-director of the National Spinal Cord Injury Statistical Center.

    In 1988, Dr. Fine was appointed Professor of Medicine in the UAB Depart-ment of Medicine’s Division of Clinical Immunology and Rheumatology.

    During his nearly four decade long career at UAB, Dr. Fine held secondary appointments in the UAB School of Public Health’s Department of Health Care Organization and Policy, the School of Public Health’s Department of Epidemiology, the School of Nursing and in UAB’s Graduate School.

    Dr. Fine is a Fellow of the American College of Epidemiology and a member of numerous professional organizations, including the American Congress of Rehabilitation Medicine, the World Federation of Neurology, the New York Academy of Sciences, and the Society of Sigma Chi. Dr. Fine served as chairman of the late Governor George Wallace’s Task Force on Drunk Driving for the state of Alabama and is cofounder of Mothers Against Drunk Driving in Alabama, serving as president of that organization in Jefferson County from 1984 to 1986.

    Dr. Fine is the author or coauthor of more than 100 contributions to scientific literature and has been awarded numerous funded and peer-reviewed scientific research grants and contracts that brought nearly $50 million to UAB during his tenure.

    In 1993, the story of his relationship with a despondent quadriplegic contemplating suicide was the subject of The Switch, an Emmy nominated made-for-television movie that was broadcast nationwide on the CBS television network.



    Click here for a more complete list of publications. Below are a few selected papers

    Fine, P.R
    ., Thomas, C.W., Suhs RH, Cohnberg RE, Flashner BA. 1972. Pediatric blood lead levels: a study in 14 Illinois cities of intermediate population. JAMA 221: 1475-1484. PMID:5068647

    Fine, P.R.
    , Kuhlemeier, K.V., DeVivo MJ, Stover SL. 1979. Spinal cord injury: an epidemiologic perspective. Paraplegia 17: 237-250. PMID: 492764

    Better, S.R., Fine, P.R., Simison D, Doss GH, Walls RT, McLaughlin DE. 1979. Disability benefits as disincentives to rehabilitation. Milbank Mem. Fund Q. 57: 412-427. PMID: 157443

    DeVivo, M.J., Fine, P.R., Maetz HM, Stover SL. 1980. Prevalence of spinal cord injury: a re-estimation employing life-table techniques. Arch. Neurol. 37: 707-708. PMID: 7436813 (From the Department of Rehabilitation Medicine and the Regional Spinal Cord Injury System (Mr DeVivo, Drs Fine and Stover), and the Department of Public Health, Division of Epidemiology (Dr Maetz), University of Alabama, Birmingham)

    Fine, P.R.,
    Roseman, J.M., Constandinou CM, Brissie RM, Glass JM, Wrigley JM. 1994. Homicide Among Black Males in Jefferson County, Alabama 1978-1989, J. Forensic Sci. 39: 674-684. PMID:8006616



  • Gaffo Oct2015Associate Professor of Medicine
    Associate Director, Rheumatology Fellowship Training Program
    Rheumatology Section Chief, Birmingham VA Medical Center



    Shelby Bldg., room 306

    Telephone:(205) 975-8909



    MD:Universidad Peruana Cayetano Heredia, 1991-1999, Lima, Peru 
    Residency: Internal Medicine, University of Alabama at Birmingham, 2002-2005

    Rheumatology, University of Alabama at Birmingham, 2005-2007
    Quality Improvement, National VA Quality Scholars Program at the Birmingham VA Medical Center, 2007-2009

    Postgraduate:MSPH in Epidemiology, University of Alabama at Birmingham School of Public Health, 2006-2008)


    Clinical Interests

    • General Rheumatology Practice with emphasis in connective tissue diseases and metabolic crystal disorders.
    • Quality improvement in musculoskeletal disease.
    • Care of patients with vasculitis


    Research interests

    • Epidemiology of hyperuricemia and gout, with focus on their association with ethnic, dietary, and cardiovascular factors
    • Quality of care in arthritis and rheumatic diseases
    • Clinical and therapeutic aspects of vasculitis care



    Click here for a more complete list of publications. Below are selected papers

    Sattui SE, Singh JA, Gaffo AL. 2014. Comorbidities in patients with crystal diseases and hyperuricemia. Rheum Dis Clin North Am. 40(2):251-78. PMID: 24703346 PMCID: PMC4159668

    Gaffo AL, Jacobs DR Jr, Sijtsma F, Lewis CE, Mikuls TR, Saag KG. 2012. Serum urate association with hypertension in young adults: analysis from the Coronary Artery Risk Development in Young Adults cohort. Ann Rheum Dis. 2012 Sep 14. [Epub ahead of print]PMID:22984170

    Gaffo AL, Jacobs DR Jr, Lewis CE, Mikuls TR, Saag KG. 2012. Association between being African-American, serum urate levels and the risk of developing hyperuricemia: findings from the Coronary Artery Risk Development in Young Adults cohort. Arthritis Res Ther. 14(1):R4. PMID:22225548

    Gaffo AL, Schumacher HR, Saag KG, Taylor WJ, Dinnella J, Outman R, Chen L, Dalbeth N, Sivera F, Vázquez-Mellado J, Chou CT, Zeng X, Perez-Ruiz F, Kowalski SC, Goldenstein-Schainberg C, Chen L, Bardin T, Singh JA. 2012. Developing a provisional definition of flare in patients with established gout. Arthritis Rheum. 64(5):1508-17. PMID:22083456



  • Gibson_2012Assistant Professor of Medicine



    Shelby Bldg, Room 203
    1825 University Blvd.

    Telephone:(205) 975-6407

    Fax:(205) 996-6734



    BS (Biology), City University of New York, Brooklyn College, 1984
    PhD (Genetics), City University of New York, Graduate School, 1995
    MBA, American Intercontinental, Atlanta,GA, 2003
    Postdoctoral Training, Cornell University Medical College/Hospital for Special Surgery, 1995-1996
    Postdoctoral Training, University of Alabama at Birmingham, 1996-1999


    Research Interests:

    Molecular genetics and epigenetics of autoimmune diseases: Characterization of genetic variants on the SLE-linked q21-q42 region of chromosome 1; Structure and function of Fc gamma receptors in inflammation.



    Click here for a more complete list of publications. Below are a few selected papers.

    Shah S, Gibson AW, Ji C, Darrington E, Mobley J, Kojima K, Edberg JC, Kimberly RP. 2016. Regulation of FcRγ function by site-specific serine phosphorylation. J Leukoc Biol. 101(2):421-428. PMID: 27630214 PMCID: PMC5235907

    Li X, Gibson AW, Kimberly RP. 2014. Human FcR polymorphism and disease. Curr Top Microbiol Immunol. 382:275-302. PMID: 25116105.

    Absher DM, Li X, Waite LL, Gibson A, Roberts K, Edberg J, Chatham WW, Kimberly RP. 2013. Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell populations. PLoS Genet. 9(8):e1003678. PMID: 23950730 PMCID: PMC3738443

    Gibson AW, Li X, Wu J, Baskin JG, Raman C, Edberg JC, Kimberly RP. 2012. Serine phosphorylation of FcγRI cytoplasmic domain directs lipid raft localization and interaction with protein 4.1G. J Leukoc Biol. 91(1):97-103. PMID:22003208. Free PMC Article

    Gibson AW, Li FJ, Wu J, Edberg JC, Su K, Cafardi J, Wiener H, Tiwari H, Kimberly RP, Davis RS. 2009. The FCRL3 -169CT promoter single-nucleotide polymorphism, which is associated with systemic lupus erythematosus in a Japanese population, predicts expression of receptor protein on CD19+B cells. Arthritis Rheum. 60(11):3510-2.  PMID: 19877046

  • Heck-2011Professor of Medicine


    Faculty Office Tower, Room 858B




    MD, Indiana University School of Medicine, 1973
    Internship, Indiana University Hospitals
    Residency, Indiana University Hospitals
    Postdoctoral Training, Harvard Medical School

    Research Interests

    Pathogenesis and treatment of rheumatoid arthritis.

    Selected Publications

    Chaiamnuay S, Heck LW, Bell WC, Bastian HM. 2007. Acute granulomatous lupus pneumonitis: the first case report. Lupus. 16(3):201-4. Review. PMID: 17432106

    Brandt KD, Mazzuca SA, Katz BP, Lane KA, Buckwalter KA, Yocum DE, Wolfe F, Schnitzer TJ, Moreland LW, Manzi S, Bradley JD, Sharma L, Oddis CV, Hugenberg ST, Heck LW. 2005. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum. 52(7):2015-25. PMID: 15986343

    Moreland LW, Morgan EE, Adamson TC 3rd, Fronek Z, Calabrese LH, Cash JM, Markenson JA, Matsumoto AK, Bathon J, Matteson EL, Uramoto KM, Weyand CM, Koopman WJ, Heck LW, Strand V, Diveley JP, Carlo DJ, Nardo CJ, Richieri SP, Brostoff SW. 1998. T cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vbeta3, Vbeta14, and Vbeta17 peptides. Arthritis Rheum. 41(11):1919-29. PMID: 9811045

    Moreland LW, Heck LW Jr, Koopman WJ. 1997. Biologic agents for treating rheumatoid arthritis. Concepts and progress. Arthritis Rheum. 40(3):397-409. Review.  PMID: 9082924

    Jaworski TM, Bradley LA, Heck LW, Roca A, Alarcón GS. 2005. Development of an observation method for assessing pain behaviors in children with juvenile rheumatoid arthritis. Arthritis Rheum. 38(8):1142-51. PMID: 7639812



  • Hsu 2017Associate Professor of Medicine


    Shelby Building, Room 311
    1825 University Boulevard


    Telephone:(205) 934-8909
    Fax: 205-975-6648
    Email: rheu078@uab.edu

    Dr. Hsu's webpage in the School of Medicine



    BS, Chinese Culture University, Taipei, Taiwan, 1986
    MS,Rutgers University, New Brunswick, NJ, 1990
    PhD,Rutgers University, New Brunswick, NJ, 1995
    Postdoctoral Fellow,University of Alabama at Birmingham, 1999


    Research Description

    We have identified that autoimmune BXD2 mice exhibit unique features, including spontaneous formation of germinal centers, increased expression of activation-induced cytidine deaminase (AID), increased production of pathogenic autoantibodies that are polyreactive, significantly increased percentage of IL-17high CD4 TH cells (TH-17) and IL-17Rhigh B cells, and significantly increased numbers of type I interferon producing plasmacytoid dendritic cells in the spleens of these mice. We are currently studying the inter-connection of high IL-17, high type I IFN and the development of autoreactive B cells related to B-cell tolerance loss at the transitional stage and the germinal center stage in BXD2 mice.

    We currently study the close interaction between spleen marginal zone (MZ) B cells and MZ macrophages, and the implication of disrupting this close interaction in disease relapse following B-cell depletion therapy (BCDT) in systemic lupus erythematosus (SLE). In healthy individuals, the MZ B cells provide essential signals to maintain MZM survival and tolerogenic signaling to apoptotic debris derived autoantigens (AC-Ags) in the spleen MZ barrier. In SLE, a deficiency of tolerogenic MZMs occurs which disrupts the barrier and promotes an immunogenic environment including accumulation of uncleared AC-Ags and production of type I IFNs. Based on these results, we propose that BCDT in lupus, through depletion of the MZ B cells leads to a secondary depletion of the MZMs which may enable immunogenic responses to ACs in certain SLE patients. During deep B-cell depletion, when there are minimal B cells, this effect is not apparent. However, as B-cell repopulation occurs, the B cells are immediately subject to the immunogenic MZ microenvironment resulting in formation of autoreactive B cells and disease flares. We are currently developing strategies to overcome the loss of tolerogenic MZM barrier following BCDT with an ultimate goal to re-set B-cell tolerogenic state to achieve long-term remission. This work is currently supported by the Lupus Research Institute. http://lupusresearchinstitute.org/lupus-research/grant-recipients/hsu/hui-chen



    Click here for a more complete list of publications on PubMed. Below are a few selected papers.

    Li H, Fu Y-X, Wu Q, Zhou Y, Crossman DK, Yang PA, Li J, Luo B, Morel LM, Kabarowski JH, Yagita H, Ware C, Hsu H-C, Mountz JD. 2015. Interferon-induced Defective Mechanosensing Signaling in Lupus Spleen Marginal Zone Macrophages. J Clin Invest. 125(7):2877-90. PMC4563689

    Hamilton JA, Li J, Wu Q, Yang PA, Luo B, Li H, Bradley JE, Taylor JE, Randall TD, Mountz JD, and Hsu H-C. 2015. General Approach for Tetramer Based Identification of Autoantigen Reactive B Cells: Characterization of La and snRNP Reactive B Cells in Autoimmune BXD2 Mice. J Immunol, 194(10):5022-34. PMC4417409

    Li H, Hsu H-C, Wu Q, Yang PA, Li J, Luo B, Cua D, Oukka M, Steele III CH, Grizzle, WE, and Mountz JD. 2014.  IL-23 promotes TCR-mediated negative selection of thymocytes through the upregulation of IL-23 receptor and RORγt. Nat Commun. 5:4259.  PMC4136447

    Li H, Wu Q, Li J, Yang P, Zhu Z, Luo B, Hsu H-C, and Mountz JD. 2013. Cutting Edge: Defective follicular exclusion of apoptotic antigens due to marginal zone macrophage defects in autoimmune BXD2 mice. J Immunol 190(9):4465-9. PMC3656168.

    Wang JH, New JS, Xie S, Yang PA, Wu Q, Li J, Luo B, Ding Y, Druey KM, Hsu H-C, and Mountz JD. 2013. Extension of the germinal center stage of B-cell development promotes autoantibodies in BXD2 mice. Arthritis & Rheum 65(10), 2703-2712. (Supplementary Table) PMC3979745


  • laura_hughesProfessor of Medicine
    Director, Rheumatology Fellowship Training Program



    Shelby Bldg, Room 178G
    1825 University Blvd.

    Telephone: (205) 934-7995
    Fax:(205) 996-6734



    BS (Zoology), Auburn University, Auburn, Alabama, 1991, cum laude
    MD, University of Alabama at Birmingham, Birmingham, Alabama, 1996, with Scholastic Excellence
    Internship and Residency (Internal Medicine), Carraway Methodist Medical Center, Birmingham, Alabama, 1996-1999
    Chief Resident (Internal Medicine), Carraway Methodist Medical Center, Birmingham, Alabama, 1999-2000
    Clinical Fellow (Internal Medicine), Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama , 2001-2003
    MSPH (Clinical Trials/Biostatistics), University of Alabama at Birmingham, Birmingham, Alabama, 2001-2003


    Research Interests:

    Dr. Hughes’ research interest is in identifying pharmacogenetic markers for treatment response and toxicity in subjects with rheumatoid arthritis. She has also investigated genetic markers for susceptibility and severity in African-American subjects with rheumatoid arthritis. Her research interests have recently expanded to include analysis of genetic markers in inflammatory and adipokine genes for association with osteoarthritis.



    Click here for a more complete list of publications. Below are a few selected papers.

    Tamhane A, McGwin G Jr, Redden DT, Hughes LB, Brown EE, Westfall AO, Reynolds RJ, Conn DL, Jonas BL, Smith EA, Brasington RD, Moreland LW, Bridges SL Jr, Callahan LF. 2013. Complementary and alternative medicine use in african-americans with rheumatoid arthritis. Arthritis Care Res (Hoboken). 66(2):180-189. PMID:23983105

    Reynolds RJ, Cui X, Vaughan LK, Redden DT, Causey Z, Perkins E, Shah T, Hughes LB; CLEAR Investigators, Damle A, Kern M, Gregersen PK, Johnson MR, Bridges SL Jr. 2013. Gene expression patterns in peripheral blood cells associated with radiographic severity in African Americans with early rheumatoid arthritis. Rheumatol Int. 33(1):129-37. PMID:22238028 PMCID:PMC3769702

    Perkins EA, Landis D, Causey ZL, Edberg Y, Reynolds RJ, Hughes LB, Gregersen PK, Kimberly RP, Edberg JC, Bridges SL Jr; Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis Investigators. 2012. Association of single-nucleotide polymorphisms in CCR6, TAGAP, and TNFAIP3 with rheumatoid arthritis in African Americans. Arthritis Rheum. 64(5):1355-8. PMID:22127930

    Guermazi A, Roemer FW, Hayashi D, Crema MD, Niu J, Zhang Y, Marra MD, Katur A, Lynch JA, El-Khoury GY, Baker K, Hughes LB, Nevitt MC, Felson DT. 2011. Extended report: assessment of synovitis with contrast-enhanced MRI using a whole-joint semiquantitative scoring system in people with, or at high risk of, knee osteoarthritis: the MOST study. Ann Rheum Dis. 70(5):805-11.  PMID: 21187293

    Hughes LB, Reynolds RJ, Brown EE, Kelley JM, Thomson B, Conn DL, Jonas BL, Westfall AO, Padilla MA, Callahan LF, Smith EA, Brasington RD, Edberg JC, Kimberly RP, Moreland LW, Plenge RM, Bridges SL Jr. 2010. Most common single-nucleotide polymorphisms associated with rheumatoid arthritis in persons of European ancestry confer risk of rheumatoid arthritis in African Americans. Arthritis Rheum. 62(12):3547-53. PMID: 21120996



  • RevTracy Hwangpo smallInstructor of Medicine

    Division of Clinical Immunology and Rheumatology


    Shelby Building, Room 412
    1825 University Boulevard
    Birmingham, AL 35294-1711

    Telephone: (205) 934-7427

    Fax: (205) 934-1564

    Email: thwangpo@uabmc.edu


    (Biology with Honors): Haverford College, 2000
    Ph.D.(Biomedical Sciences): Mount Sinai's Graduate School of Biomedical Sciences, 2007
    M.D.: Icahn School of Medicine at Mount Sinai, 2008
    Intern (Medicine): University of Alabama at Birmingham School of Medicine, Birmingham, AL, 2008-2009
    Resident (Medicine): University of Alabama at Birmingham School of Medicine, Birmingham, AL, 2009-2011
    Postdoctoral Fellow (Immunology): University of Alabama at Birmingham School of Medicine, Birmingham, AL, 2011-2014
    Clinical Fellow (Allergy & Immunology), University of Alabama at Birmingham School of Medicine, Birmingham, AL, 2012-2014

    Research Interests


    The focus of my research is the characterization of immune abnormalities in patients with recurrent sino-pulmonary infections with subnormal immunoglobulin levels, who do not meet criteria for Common Variable Immunodeficiency (CVID). As a clinician, I am interested in classifying those patients, as well as patients with classical CVID by severity and following the course of changes in their immune system to find clues that may suggest ways to treat their unspecified immunodeficiency. As a researcher, I have used several criteria to explore the immune abnormalities in this specific cohort: (a) Changes in B cell subsets as a function of time; (b) Functional antibody response; (c) HLA typing to examine the propensity for development of immunodeficiency; and (d) Examination of rare SNPs that may correlate with the severity of their immune system abnormalities.



    Wang Y, Hwangpo T, Martin MP, Vince N, Qi Y, Reynolds RJ 4th, Absher D, Gao X, Ballinger CA, Burrows PD, Atkinson TP, Brown EE, Elgavish A, Liu C, Carrington M, Schroeder HW.J 2016. Killer cell immunoglobulin-like receptors are associated with common variable immune deficiency pathogenesis. Allergy Clin Immunol. 138:1495-1498. PMID: 27665490 PMCID: PMC5104182

    Mroczek, E, Ippolito, GC, Rogosch, T, Hoi, KH, Hwangpo, TA, Brand, MG Zhuang, Y, Liu,C, Schneider, D, Zemlin, M, Brown, EE, Georgiou, G, and Schroeder, HW. Differences in the composition of the human antibody repertoire by B cell subsets in the blood. Front. Immunol. 5:96, 2014. PMCID: PMC3958703

    Hwangpo, TA, Jordan, JD, Premsiriut,P, Jayamaran, G, Licht, J, Iyengar, R, and Neves, SR. GRIN modulates Sprouty repression of MAPK activation by growth factor stimulation. Journal of Biological Chemistry 287(17):13674-85. 2012. PMCID: PMC3340172




SOM Epilogue Menu